National Institute on Aging logo
Program

Alzheimer's Drug-Development Program (ADDP)

Funds preclinical and clinical drug development for Alzheimer disease through cooperative pathways.

National Institute on AgingUnited StatesCooperative agreement
About

The Alzheimer's Drug-Development Program (ADDP), funded under PAR-24-223 / PAR-25-297 (U01), supports drug discovery and development studies targeting AD/ADRD. The U01 cooperative agreement means NIA scientific staff actively engage in project design and direction. Program expires November 6, 2027.

Industries covered
BiotechMedtechNeurotech
Grants under Alzheimer's Drug-Development Program (ADDP)

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.

NIA Alzheimer's Drug-Development Program
Open

Funds collaborative research alliances that accelerate Alzheimer's drug development in the United States.

— pool·489 days
Last verified: 29 May 2026Source: grants.nih.gov